Related Experiment Video
Updated: Apr 19, 2026
04:42
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
Published on: June 26, 2018
15.3K
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain
Aaron Yarlas1, Kate Miller, Warren Wen
1Optum , Lincoln, RI.
Postgraduate Medicine
|December 20, 2014
Summary
The buprenorphine transdermal system (BTDS) effectively reduces pain interference in physical and emotional functioning for chronic low back pain (CLBP) patients. This improvement was evident within four weeks and sustained throughout the 12-week study.
Area of Science:
- Pain Management
- Pharmacology
- Clinical Trials
Background:
- Chronic low back pain (CLBP) significantly impacts physical and emotional functioning.
- Effective pain management strategies are crucial for improving quality of life in CLBP patients.
Purpose of the Study:
- To evaluate the efficacy of the buprenorphine transdermal system (BTDS) in mitigating pain interference.
- To assess the impact of BTDS on physical and emotional functioning in patients with moderate-to-severe CLBP.
Main Methods:
- A post-hoc analysis of a randomized, placebo-controlled, double-blind trial.
- Utilized Brief Pain Inventory (BPI) to measure pain interference over 12 weeks.
- Compared BTDS versus placebo for BPI subscale scores, change patterns, and patient-reported outcomes.
Main Results:
- BTDS treatment resulted in significantly lower mean BPI Interference scores compared to placebo (P < 0.001).
- Differences in pain interference emerged within 4 weeks and were maintained for 12 weeks.
- BTDS patients showed significantly greater likelihood of reporting mild/no interference and criterion-level improvements.
Conclusions:
- The buprenorphine transdermal system (BTDS) is effective in reducing pain interference in CLBP.
- BTDS demonstrates a rapid onset of action, with benefits observed within 4 weeks.
- BTDS offers a viable treatment option for improving functioning in CLBP patients.
Keywords:
Butransbuprenorphine transdermal systemchronic low back painopioid treatmentpain interferenceMore Related Videos
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
01:25Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
01:18Transdermal Drug Delivery Systems
195
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
195
01:26Oral Drug Delivery Systems: Continuous-Release Systems
271
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
271
01:21Drugs for Treatment of Constipation-Predominant IBS
1.4K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
970
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
970